Cargando…
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
Biosimilar medicines support the sustainability of national healthcare systems, by reducing costs of biological therapies through increased competition. However, their adoption into clinical practice largely depends on the acceptance of healthcare providers and patients. Patients are different from...
Autores principales: | Vandenplas, Yannick, Simoens, Steven, Van Wilder, Philippe, Vulto, Arnold G., Huys, Isabelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913743/ https://www.ncbi.nlm.nih.gov/pubmed/33557030 http://dx.doi.org/10.3390/ph14020117 |
Ejemplares similares
-
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022) -
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021) -
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
por: Vandenplas, Yannick, et al.
Publicado: (2023) -
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019) -
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)